Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment-Reference-Cited by-同舟云学术

Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment

Published:2023-10-23 Issue:6 Volume:26 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Sahin Ahmet¹,Caner Burcu²,Ocak Birol³,Gulmez Ahmet⁴,Hamitoglu Buket⁵,Cubukcu Erdem³,Deligonul Adem³,Orhan Sibel³,Canhoroz Mustafa⁶,Odman Hikmet³,Somali Isil⁵,Ocakoglu Gokhan⁷,Evrensel Turkkan³

Affiliation:

1. Department of Medical Oncology, School of Medicine, Usak University, Usak 64100, Turkey

2. Department of Medical Oncology, Atatürk City Hospital, Altieylul, Balıkesir 10100, Turkey

3. Department of Medical Oncology, School of Medicine, Uludag University, Nilufer, Bursa 16059, Turkey

4. Department of Medical Oncology, School of Medicine, Inonu University, Battalgazi, Malatya 44280, Turkey

5. Department of Medical Oncology, School of Medicine, Dokuz Eylul University, Konak, İzmir 35210, Turkey

6. Department of Medical Oncology, Bursa Medicana Hospital, Nilufer, Bursa 16110, Turkey

7. Department of Biostatistics, School of Medicine, Uludag University, Nilufer, Bursa 16059, Turkey

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference45 articles.

1. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

2. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013;Noone;Cancer Epidemiol Biomarkers Prev,2017

3. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

4. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

5. Antibody drug conjugate: The ‘biological missile’ for targeted cancer therapy;Fu;Signal Transduct Target Ther,2022